Xiaojin Shi

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

Melissa L. Johnson, Byoung Chul Cho, Alexander Luft et al. · Journal of Clinical Oncology · 2022 · 434 citations · Full text

Medicine, Oncology, Pharmacology +17

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa et al. · The Lancet Oncology · 2015 · 410 citations

Medicine, Oncology, Pharmacology +15

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

Yung‐Jue Bang, Rui‐Hua Xu, Keisho Chìn et al. · The Lancet Oncology · 2017 · 291 citations · Full text

Medicine, Oncology, Pharmacology +11

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Tony Mok, Sang‐We Kim, Yi‐Long Wu et al. · Journal of Clinical Oncology · 2017 · 187 citations

Medicine, Oncology, Pharmacology +17

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

Takashi Seto, Taito Esaki, Fumihiko Hirai et al. · Cancer Chemotherapy and Pharmacology · 2013 · 101 citations

Medicine, Oncology, Pharmacology +6